Presented by respected leaders in heart failure, our live and recorded webinars highlight the role of ST2 and its clinical utility in heart failure management.

UTilizing st2 in the management of heart failure patients

Presented by: Alan S. Maisel, MD, FACC, Professor of Medicine, UCSD, Director, CCU and Heart Failure, SD VA Medical Center

Date: September 8, 2016 (Thursday)  
Time: 4:00 pm – 5:00 pm (EDT)

ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity and renal impairment. This live webinar will be highlighting real-life clinical case studies where ST2 provides incremental information above and beyond existing clinical tools, like the natriuretic peptides, in the management of heart failure patients.

View Recording >> 

Practical utility of biomarkers in heart failure management

Presented by: Chris M. Bell, RN, MSN, ACNP, Heart Failure and Arrhythmia Management, Cardiology Associates of North Mississippi

Date: November 17, 2015 (Tuesday)  
Time: 1:00 pm – 2:00 pm (EDT)

Cardiac biomarkers are widely used in the management of heart failure patients.  However, not all biomarkers are the same, and while the natriuretic peptides have established roles in the diagnosis of heart failure, there are new biomarkers, like ST2, that have a specific role in prognosis.  Knowledge of how ST2 can complement existing biomarkers is critical in integrating it in the clinical setting.

View Recording >> 

ST2 for Prognosis and Management of Heart failure

Presented by: Alan S. Maisel, MD, Professor of Medicine, University of California San Diego, Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs, San Diego Healthcare System

Date: March 26, 2014 (Wednesday)  
Time: 12:00 pm – 1:00 pm (EDT)

The tremendous burden of heart failure on our society necessitates novel ways to reduce costs, risk stratify our patients and personalize treatment so as to achieve better results. To this end, ST2 is one of the up and coming cardiac biomarkers available today. It is a marker of fibrosis and remodeling and provides us with significant prognostic guidance, without confounders such as age and obesity. This talk will explore the uses of ST2 in a number of clinical settings. We will start in the setting of acute heart failure where readmission rates of up to 30 percent at thirty days necessitate better risk stratification. ST2 should be part of that strategy. In the ambulatory heart failure arena, alterations in ST2 levels often forewarn of impending decompensation, while at the same time, good treatment will lower ST2 levels and improve prognosis. We will then talk about how ST2 levels can be used to guide and personalize treatment. We will finish with some clinical studies.

View Recording >>

Utilizing Cardiac Biomarker ST2 in the management of heart failure patients: Clinical case studies

Presented by: James Januzzi, MD, FACC, FESC, Massachusetts General Hospital

Date: July 10, 2013 (Wednesday)  
Time: 7:00 am – 8:00 am (ET)

Clinically, in patients with heart failure (HF), elevated concentrations of ST2 are strongly associated with disease severity and identifies patients where their disease is worsening. Consequently ST2 is a powerful predictor of increased risk of complications, independent and additive of other established or emerging biomarkers.  The alarming rate of rehospitalisation associated with HF has challenged clinicians and ST2's prognostic strength has a potential role in identifying high risk patients requiring more intensive and personalized care. 

The American College of Cardiology Foundation/American Heart Association Task Force jointly released its expanded 2013 clinical practice guideline for the management of patients with heart failure and has identified ST2 "not only predictive of hospitalization and death in patients with HF [heart failure] but also additive to natriuretic peptide levels in [its] prognostic value." 

In this webinar, Dr. James Januzzi, from Massachusetts General Hospital, will provide an overview of ST2's prognostic strength and highlight how it can improve the management of heart failure patients through clinical case studies.

View Recording >>

Practical Use of Novel Biomarker ST2 in Chronic Heart Failure Prognosis

Presented by: Lori Daniels, MD, UC San Diego, Director, Coronary Care Unit Sulpizio Cardiovascular Center La Jolla, CA

Date: May 7, 2013 (Tuesday)  
Time: 8:00 pm – 9:00 pm (ET)

Clinical uptake of the natriutretic peptides, BNP and NT-proBNP, in the area of prognosis has been anything like its widespread utility in the diagnosis of heart failure. Due to the unreliability of results in the presence of common confounding factors like BMI and renal impairment, as well as the significant change required to be clinically meaningful, make the natriuretic peptides less suitable as a prognostic marker. ST2 is a novel cardiac biomarker that reflects a unique and distinct pathway from the natriuretic peptides, which provides independent and complementary information to existing clinical tools that improves prognosis in heart failure patients.

View Recording >>

Role of cardiac biomarkers in preventing 30-day readmission in chronic heart failure patients

Presented by: Amy Saenger, Ph.D., DABCC, Cardiovascular Laboratory Medicine, Mayo Clinic

Date: April 24, 2013 (Wednesday)  
Time: 12:00 pm – 1:00 pm (ET)

The natriuretic peptides have established a role in the diagnosis of heart failure, however, their ability to bridge the gap in prognosis has fallen short, as evidenced by the high 30-day rehospitalization rate.  The evidence for novel cardiac biomarkers that reflect unique and distinct pathways in heart failure has been promising.  As highlighted in some key clinical publications, they provide additional information above and beyond natriuretic peptides, which enables the delivery of timely and focused care that may significantly improve outcomes.  Amy Saenger, Ph.D. from Mayo Clinic will highlight in this webinar the clinical utility of next generation cardiac biomarkers in heart failure management.

View Recording >>

Practical Utility of Cardiac Biomarker ST2, in Heart Failure Management

Presented by: Antoni Bayes-Genis, MD,   Chair Cardiology Service, Hospital Universitari Germans Trias i Pujol

Date: March 21, 2013 (Thursday) 
Time: 11:00 am – 12:00 pm (ET)

While there are established clinical tools to diagnose heart failure, the tools are somewhat weak in prognosing outcome in these same patients. In a study led by Dr. Antoni Bayes-Genis and Dr. Josep Lupon, ST2 has been shown to be a stronger cardiac marker than NT-proBNP in the risk stratification of heart failure patients. ST2 reflects a distinct pathway of heart failure which provides additional information that enables the delivery of focused care to those patients needing it most in a timely fashion, which has the potential to significantly improve outcomes.  As a result, ST2 has been implemented into the Hospital Universitari Germans Trias I Pujol, in Badalona, Spain as a routine clinical tool to better risk stratify heart failure patients.  This webinar highlights the study findings and the practical utility of ST2 in the management of heart failure patients.

View Recording >>

Beyond The Natriuretic Peptides for Management of Heart Failure: An Expert Panel Review of a Novel Biomarker, ST2

Presented by: James Januzzi, MD, James Snider, Ph.D., Anthony Joseph, MD 

Heart failure is a chronic progressive illness that challenges the best clinician. Disease progression is often masked by absence of observable clinical changes, while the neuro-hormonal abnormalities continue unabated. While the natriuretic peptides have established a role in the diagnosis of heart failure, their ability to bridge the gap in prognosis has fallen short in the management of these patients. Novel cardiac biomarkers, like ST2, provide additional information that enables the delivery of focused care to those patients needing it most in a timely fashion, which has the potential to significantly improve outcomes. 

Obtain username and password by contacting us at to access the webinar. Watch >>


Video of james januzzi, md
Dr. James Januzzi talks about the scientific evidence and clinical utility of ST2.

Video of Antoni Bayes-Genis, MD
Dr. Antoni Bayes-Genis speaks about ST2's strength in prognosis over NT-proBNP in a video that accompanies a recent Mayo Clinic Proceedings publication.

online cme
Register online for CME course highlighting 30-day rehospitallization and use of biomarkers.

Sign up to receive notifications when new content is posted.


Yes, I would like to receive emails from Critical Diagnostics.
Please enter the text you see in the image: